Oncorus

Oncorus Non-Current Assets

Delisted

The Non-Current Assets of Oncorus (ONCR) as of Oct 17, 2026 is 16.30 M USD. In the previous year, Non-Current Assets was -56.60 M USD — a change of -128.80% (higher).

Non-Current Assets

16.30 MUSD

YoY

-128.80%

Last updated:

Non-Current Assets of Oncorus is 2022 16.30 M USD. Non-Current Assets of Oncorus was 2021 -56.60 M USD. It decreases by -128.80% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncorus Stock analysis

What does Oncorus do? Oncorus Inc, based in Andover, Massachusetts, develops viral immunotherapies for cancer treatment. The company focuses on a self-amplifying RNA platform, with product candidates ONCR-021 for non-small cell lung cancer and other solid tumors, and ONCR-788 targeting Seneca Valley Virus. Oncorus employs 64 full-time staff and went public on 2 October 2020. Its research aims to enhance anti-tumor immunity through viral-based therapies. Oncorus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncorus stock

Non-Current Assets of Oncorus is 16.30 M USD in 2022.

Non-Current Assets of Oncorus changed from -56.60 M USD to 16.30 M USD, representing a -128.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Non-Current Assets Oncorus since 2006 – with annual values, charts, and detailed analysis.

Non-current assets are long-term resources not expected to be converted to cash within one year, including property, equipment, and long-term investments.

Non-Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Non-Current Assets's Oncorus historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Oncorus

All Key Metrics — Oncorus